Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer - Trial NCT06035679
Access comprehensive clinical trial information for NCT06035679 through Pure Global AI's free database. This phase not specified trial is sponsored by Youzhi Zhu and is currently Not yet recruiting. The study focuses on Breast Cancer Female. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Youzhi Zhu
First Affiliated Hospital of Fujian Medical University
Timeline & Enrollment
N/A
Sep 20, 2023
Nov 30, 2026
Primary Outcome
tpCR
Summary
This study is a prospective, single-center, observational clinical study, The objection was
 to observe the treatment of pyrotinib combined with trastuzumab and neoadjuvant chemotherapy
 Efficacy of Stage II-III breast cancer and observation of the efficacy of step-down
 neoadjuvant therapy for HER2-positive stage T1cN0M0 breast cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06035679
Non-Device Trial